Actinium Pharmaceuticals: NYSE Accepts Compliance Plan; Listing Extended

What Happened
Actinium Pharmaceuticals, Inc. (ATNM) announced that NYSE Regulation has accepted the company’s compliance plan and granted a plan period through November 27, 2027 to regain compliance with NYSE American listing standards. The company originally received a notice of noncompliance on May 27, 2026, submitted its compliance plan on June 18, 2026, and received NYSE Regulation’s acceptance on August 12, 2026; a related press release was issued on August 14, 2026.

Key Details

• NYSE American found the company not in compliance with Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide.
• Compliance plan submitted: June 18, 2026; NYSE acceptance letter dated August 12, 2026.
• Plan Period granted through November 27, 2027; common stock will remain listed and tradable during this period subject to progress and other listing requirements.
• If Actinium does not regain compliance or make satisfactory progress during the Plan Period, NYSE Regulation may initiate delisting proceedings.

Why It Matters
For investors, the filing means Actinium’s shares remain listed and tradable on NYSE American for now, but there is a clear timeline and conditions for the company to fix the listing deficiencies. Investors should watch for periodic updates on the company’s progress under the compliance plan and be aware that failure to meet the plan’s milestones could put the listing at risk. The filing also contains standard forward-looking statement cautions—there is no assurance the company will regain compliance.